The 2009 NCCN guidelines recommend that patients should be further divided into: (1) Good early prognosis group: stage I-II without B symptoms or large mediastinal masses; this group should be treated with ABVD as the standard chemotherapy regimen. (2) Early poor prognosis group: Stage I-II with poor prognostic factors, which are defined by most clinical trials as ESR ≥ 50, > 3 lesions, > 2 extra nodal lesions, mixed cell type or lymphocytic decompensation, age ≥ 40 or 50 years, etc., in addition to large mediastinal masses and B symptoms; 2×BEACOPP intensive regimen + 2×ABVD regimen is better than 4×ABVD regimen in this type of patients. scheme is superior to 4×ABVD scheme; (3) Advanced stage: i.e., stage III-IV. The poor prognostic factors for stage III-IV HL include: age ≥ 45 years, male, stage IV, albumin < 40 g/L, hemoglobin < 105 g/L, increased white blood cell count (> 15.0 × 109/L), and decreased lymphocyte count (absolute value < 0.6 × 109/L or ratio < 8% of total white blood cells). One point was added for each one met (International Prognostic Score, IPS). A 4-cycle intensive BEACOPP sequential 4-cycle basal BEACOPP regimen in this patient type has the potential to become the new standard of care.